

THE UPJOHN COMPANY

KALAMAZOO, MICHIGAN 49001, U.S.A.

Office of
WILLIAM E. NEWMAN, JR.
Licensing Director
TELEPHONE: (616) 323-6363
FACSIMILE: (616) 323-6247

May 8, 1992

Mr. Bernard M. Kosloski
Director, Life Sciences Group
Research Corporation Technologies
6840 East Broadway Boulevard
Tucson, AZ 85710-2815

Dear Bernie:

Bill Heyd and I enjoyed our meeting with you very much last week. It was good to get an update on RCT and to fill you in on our interests.

On the amino acid anticonvulsant compound, we have given additional thought to this subject and have decided that we do not have an interest in pursuing this further. Our feeling is that the series of compounds have not yet produced a member which demonstrates a lack of toxicity and although there may be theories on solving the problem, the status of this is too early for us to take an active interest. We currently do not have the resources to apply to these compounds given this early status.

Thank you very much for giving Upjohn the opportunity to consider the anticonvulsant technology. I trust you will think of us again in the future as other opportunities arise.

Sincerely,


William E. Newman, Jr.

RCT81.MKC

c: W.E. Heyd